Leading the Way in Life Science Technologies

GEN Exclusives

More »

Companies

More »

BioMoti

  • BioMoti
  • 42 New Road
  • London , E1 2AX
  • UNITED KINGDOM

BioMoti seeks to transform the treatment of cancer by targeted delivery of therapeutics to the intracellular space of cancer cells; aiming to increase efficacy whilst reducing side effects. MOTI1001 is BioMoti's lead Oncojan™ based ovarian cancer candidate. Oncojans are a new class of therapeutic microparticles that can target and gain entry to the interior of cancer cells where they slowly release drugs at the point of need whilst sparing healthy tissue. The platform is compatible with a range of drug classes from small molecule therapeutics to larger biologicals.

Related To This Company